

Pharmacy Formulary Updates for March 2020

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status March 2020:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together MCO - MA
Divigel 1.25 mg/1.25 gram gel	\$3.65
Nayzilam nasal solution	\$3.65; PA (PA applies to members 0 through 11 years of age; No PA required for members 12 years of age and older)
Vitamin E 180 mg capsule	NC
Complete Omega capsule	NC
Acetaminophen 325 mg chewable tablet	NC
Tramadol 100 mg tablet	NC;QL
Brukinsa capsule	\$3.65;PA
Givlaari subcutaneous solution	MB/RX;PA
Reblozyl subcutaneous solution	MB/RX;PA
Xenleta tablet	\$3.65
Xenleta intravenous solution	MB/RX
Jatenzo capsule	\$3.65;PA;QL
Consensi tablet	NC
Absorica LD capsule	\$3.65;PA
Asmanex HFA 50 mcg inhaler	\$3.65
Dulera HFA 50 mcg-5 mcg inhaler	\$3.65;PA
Azeschew chewable tablet	NC

Key

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- MB/RX:** Drug can be dispensed through Medical Benefit or Prescription Benefit
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy